Lan Michelle, Nguyen Thanh, Gray Shelly
Sr Care Pharm. 2020 Jul 1;35(7):318-323. doi: 10.4140/TCP.n.2020.318.
In the United States, cardiovascular disease (CVD) is the most common cause of death in older people. The use of omega-3 fatty acid supplements (nonprescription) is common in older people, despite the conflicting evidence regarding the benefits of supplements in CVD. The 2017 American Heart Association science advisory on omega-3 fatty acid supplements suggested that it is reasonable to use omega-3 fatty acids for secondary prevention in people with coronary heart disease and heart failure. This article reviewed large meta-analyses and clinical trials published since the science advisory. Two metaanalyses concluded that these supplements were not effective for secondary or primary prevention of CVD. Two large randomized, placebo-controlled clinical trials, one in people with diabetes mellitus, evaluated omega-3 fatty acid supplements for primary prevention and reported no benefit. Taken together, these findings do not support the routine dietary supplementation with omega-3 fatty acids to prevent cardiovascular events.
在美国,心血管疾病(CVD)是老年人最常见的死因。尽管关于补充剂对心血管疾病益处的证据相互矛盾,但老年人中使用ω-3脂肪酸补充剂(非处方)很常见。2017年美国心脏协会关于ω-3脂肪酸补充剂的科学咨询意见表明,对于冠心病和心力衰竭患者,使用ω-3脂肪酸进行二级预防是合理的。本文回顾了自该科学咨询意见发布以来发表的大型荟萃分析和临床试验。两项荟萃分析得出结论,这些补充剂对心血管疾病的二级或一级预防无效。两项大型随机、安慰剂对照临床试验,其中一项针对糖尿病患者,评估了ω-3脂肪酸补充剂用于一级预防,结果显示无益处。综上所述,这些发现不支持常规饮食补充ω-3脂肪酸以预防心血管事件。